ESTRO clinical practice guideline: Stereotactic body radiotherapy for spine metastases.
M Guckenberger, N Andratschke, C Belka...
https://pubmed.ncbi.nlm.nih.gov/37925107/Actively Recruiting
Led by Tianjin Medical University Cancer Institute and Hospital · Updated on 2026-09-03
50
Participants Needed
1
Research Sites
82 weeks
Total Duration
Researchers are evaluating the outcomes of high-precision postoperative stereotactic body radiotherapy SBRT using the Edge system for patients with spinal metastases from solid tumors. Spinal metastases can compress the spinal cord, causing pain, weakness, or paralysis. This observational study aims to assess whether this precise radiation treatment improves local tumor control, neurological function, reduces treatment time, and enhances quality of life. Participants receive postoperative SBRT with the Edge system, which delivers a total radiation dose of 35 Gy divided into 5 sessions 7 Gy each. The Edge system provides sub-millimeter accuracy with advanced positioning and surface monitoring to target tumors while protecting the spinal cord. The study observes patients for up to two years following treatment to evaluate various clinical outcomes. During the study, researchers will collect data on tumor control at 3 months, neurological status, survival rates, quality of life assessments, and any adverse effects such as radiation-related myelitis or esophagitis. Assessments occur at baseline, 3 months, 1 year, and 2 years post-treatment. The study will analyze these outcomes to understand the effectiveness and safety of this radiation approach, with participation lasting until the studys completion in 2028.
CONDITIONS
Postoperative Edge (RapidArc) Stereotactic Body Radiotherapy for Spinal Metastases
X
Xu Liming, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Tianjin Medical University Cancer Institute and Hospital
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Approximate duration of treatment sessions
Participants receive postoperative stereotactic body radiotherapy using the Edge system, delivered as 35 Gy in 5 sessions.
5 treatment visits
Duration - Up to 2 years post-treatment
Participants are monitored at baseline, 3 months, 1 year, and 2 years after treatment for tumor control, neurological function, quality of life, and adverse events.
Multiple follow-up visits at scheduled intervals
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Have more questions? Get in touch with our team for quick support
M Guckenberger, N Andratschke, C Belka...
https://pubmed.ncbi.nlm.nih.gov/37925107/Tianjin Medical University Cancer Institute and Hospital
Lead Sponsor